About this Journal Submit a Manuscript Table of Contents
Advances in Urology
Volume 2012 (2012), Article ID 693631, 7 pages
http://dx.doi.org/10.1155/2012/693631
Review Article

Urine Telomerase for Diagnosis and Surveillance of Bladder Cancer

Medical Oncology Department, Hospital Universitario La Paz, 28046 Madrid, Spain

Received 21 March 2012; Revised 31 May 2012; Accepted 4 June 2012

Academic Editor: Martin Schostak

Copyright © 2012 Angela Lamarca and Jorge Barriuso. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Castellano, J. Carles, E. Esteban et al., “Recommendations for the optimal management of early and advanced urothelial carcinoma,” Cancer Treatment Reviews, vol. 38, no. 5, pp. 431–441, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Bellmunt, A. Orsola, T. Wiegel, M. Guix, M. De santis, and V. Kataja, “Bladder cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 22, supplement 6, pp. vi45–vi49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. H. von der Maase, “Pemetrexed in transitional cell carcinoma of the urothelium,” Oncology, vol. 18, no. 13, supplement, pp. 48–50, 2004. View at Scopus
  5. H. Von der Maase, “Gemcitabine-containing regimens in bladder cancer: a new standard of care,” Seminars in Oncology, vol. 28, no. 3, supplement 10, pp. 1–3, 2001. View at Scopus
  6. J. Bellmunt, C. Théodore, T. Demkov et al., “Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract,” Journal of Clinical Oncology, vol. 27, no. 27, pp. 4454–4461, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. A. P. Mitra and R. J. Cote, “Molecular screening for bladder cancer: progress and potential,” Nature Reviews Urology, vol. 7, no. 1, pp. 11–20, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Tilki, M. Burger, G. Dalbagni et al., “Urine markers for detection and surveillance of non-muscle-invasive bladder cancer,” European Urology, vol. 60, no. 3, pp. 484–492, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. Z. Z. Cheng, M. J. Corey, M. Pärepalo et al., “Complement factor H as a marker for detection of bladder cancer,” Clinical Chemistry, vol. 51, no. 5, pp. 856–863, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Gibanel, M. J. Ribal, X. Filella et al., “BTA TRAK urine test increases the efficacy of cytology in the diagnosis of low-grade transitional cell carcinoma of the bladder,” Anticancer Research, vol. 22, no. 2 B, pp. 1157–1160, 2002. View at Scopus
  11. M. P. Raitanen, “The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies,” World Journal of Urology, vol. 26, no. 1, pp. 45–50, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Schwarz, M. Rechenmacher, T. Filbeck et al., “Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions,” Journal of Clinical Pathology, vol. 61, no. 3, pp. 272–277, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. F. Sarosdy, P. Schellhammer, G. Bokinsky et al., “Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer,” Journal of Urology, vol. 168, no. 5, pp. 1950–1954, 2002. View at Scopus
  14. A. P. Berger, W. Parson, A. Stenzl, H. Steiner, G. Bartsch, and H. Klocker, “Microsatellite alterations in human bladder cancer: detection of tumor cells in urine sediment and tumor tissue,” European Urology, vol. 41, no. 5, pp. 532–539, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. V. B. Lokeshwar and M. G. Selzer, “Urinary bladder tumor markers,” Urologic Oncology, vol. 24, no. 6, pp. 528–537, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. H. S. Choi, S. I. Lee, D. J. Kim, and T. Y. Jeong, “Usefulness of the NMP22BladderChek test for screening and follow-up of bladder cancer,” Korean Journal of Urology, vol. 51, no. 2, pp. 88–93, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. S. F. Shariat, C. Savage, T. F. Chromecki et al., “Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology,” Cancer, vol. 117, no. 13, pp. 2892–2897, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. A. M. Attallah, H. A. Sakr, H. Ismail, E. S. K. Abdel-Hady, and I. El-Dosoky, “An office-based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer,” British Journal of Urology International, vol. 96, no. 3, pp. 334–339, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. R. H. Getzenberg, B. R. Konety, T. A. Oeler et al., “Bladder cancer-associated nuclear matrix proteins,” Cancer Research, vol. 56, no. 7, pp. 1690–1694, 1996. View at Scopus
  20. M. Sánchez-Carbayo, E. Herrero, J. Megías, A. Mira, and F. Soria, “Comparative sensitivity of urinary cyfra 21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer,” Journal of Urology, vol. 162, no. 6, pp. 1951–1956, 1999. View at Scopus
  21. D. Fatela-Cantillo, A. Fernández-Suárez, V. Menéndez, J. A. Galán, and X. Filella, “Low utility of CYFRA 21-1 serum levels for diagnosis and follow-up in bladder cancer patients,” Journal of Clinical Laboratory Analysis, vol. 19, no. 4, pp. 167–171, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. V. B. Lokeshwar, C. Öbek, H. T. Pham et al., “Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade,” Journal of Urology, vol. 163, no. 1, pp. 348–356, 2000. View at Scopus
  23. C. C. Passerotti, M. Srougi, A. C. Bomfim et al., “Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma,” Urologic Oncology, vol. 29, no. 6, pp. 710–715, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Margulis, Y. Lotan, and S. F. Shariat, “Survivin: a promising biomarker for detection and prognosis of bladder cancer,” World Journal of Urology, vol. 26, no. 1, pp. 59–65, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Tsihlias and H. B. Grossman, “The utility of fibrin/fibrinogen degradation products in superficial bladder cancer,” Urologic Clinics of North America, vol. 27, no. 1, pp. 39–46, 2000. View at Scopus
  26. S. M. Gilbert, R. W. Veltri, A. Sawczuk et al., “Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer,” Urology, vol. 61, no. 3, pp. 539–543, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Sheinfeld, V. E. Reuter, M. R. Melamed et al., “Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation,” Journal of Urology, vol. 143, no. 2, pp. 285–288, 1990. View at Scopus
  28. G. Mowatt, S. Zhu, M. Kilonzo et al., “Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer,” Health Technology Assessment, vol. 14, no. 4, pp. 1–4, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. M. P. Herman, R. S. Svatek, Y. Lotan, P. I. Karakiewizc, and S. F. Shariat, “Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer,” Minerva Urologica e Nefrologica, vol. 60, no. 4, pp. 217–235, 2008. View at Scopus
  30. A. Bennett, “Telomerase and other novel approaches to bladder cancer detection,” Clinical Laboratory Science, vol. 21, no. 3, pp. 185–192, 2008. View at Scopus
  31. J. Parker and P. E. Spiess, “Current and emerging bladder cancer urinary biomarkers,” TheScientificWorldJournal, vol. 11, pp. 1103–1112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. S. A. Stewart and A. A. Bertuch, “The role of telomeres and telomerase in cancer research,” Cancer Research, vol. 70, no. 19, pp. 7365–7371, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. S. E. Artandi and R. A. DePinho, “Telomeres and telomerase in cancer,” Carcinogenesis, vol. 31, no. 1, Article ID bgp268, pp. 9–18, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. L. E. Donate and M. A. Blasco, “Telomeres in cancer and ageing,” Philosophical Transactions of the Royal Society B, vol. 366, no. 1561, pp. 76–84, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Brandt, “TERT over-expression affects the growth of myocardial tissue derived from mouse embryonic stem cells,” Differentiation, vol. 79, no. 1, pp. 1–8, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Chen and Q. Kong, “Nuclear translocation of telomerase reverse transcriptase: a critical process in chemical induced hepatocellular carcinogenesis,” Neoplasma, vol. 57, no. 3, pp. 222–227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. C. H. Chen and R. J. Chen, “Prevalence of telomerase activity in human cancer,” Journal of the Formosan Medical Association, vol. 110, no. 5, pp. 275–289, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. C.-C. Lee, K.-F. Huang, D.-M. Chang et al., “Design, synthesis and evaluation of telomerase inhibitory, hTERT repressing, and anti-proliferation activities of symmetrical 1,8-disubstituted amidoanthraquinones,” European Journal of Medicinal Chemistry, vol. 50, pp. 102–112, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. D. D'Ambrosio, P. Reichenbach, E. Micheli et al., “Specific binding of telomeric G-quadruplexes by hydrosoluble perylene derivatives inhibits repeat addition processivity of human telomerase,” Biochimie, vol. 94, no. 3, pp. 854–863, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. J. D. Henson, Y. Cao, L. I. Huschtscha et al., “DNA C-circles are specific and quantifiable markers of alternative- lengthening-of-telomeres activity,” Nature Biotechnology, vol. 27, no. 12, pp. 1181–1185, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. S. Lee, K. Tae, S. H. Lee et al., “Change of telomerase activity in peripheral whole blood of head and neck squamous cell carcinoma patients before and after surgery: a pilot study,” Clinical and Translational Oncology, vol. 13, no. 10, pp. 747–752, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Liu, B. Q. Wu, H. H. Zhong, M. L. Xu, and W. G. Fang, “Detection of telomerase activity in cultured cells and tumor tissue of lung carcinoma by modified telomeric repeat amplification protocol,” Pathology International, vol. 60, no. 5, pp. 386–394, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. B. Özmen, C. I. Duvan, G. Gümüş, M. Sönmezer, M. Gungor, and F. Ortaç, “The role of telomerase activity in predicting early recurrence of epithelial ovarian cancer after first-line chemotherapy: a prospective clinical study,” European Journal of Gynaecological Oncology, vol. 30, no. 3, pp. 303–308, 2009. View at Scopus
  45. H. Xin, “Telomeric repeat amplification protocol: measuring the activity of the telomerase,” Methods in Molecular Biology, vol. 735, pp. 107–111, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. A. L. McCleary-Wheeler, L. E. Williams, P. R. Hess, and S. E. Suter, “Evaluation of an in vitro telomeric repeat amplification protocol assay to detect telomerase activity in canine urine,” American Journal of Veterinary Research, vol. 71, no. 12, pp. 1468–1474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. V. Casadio, S. Bravaccini, R. Gunelli et al., “Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients,” International Journal of Biological Markers, vol. 24, no. 4, pp. 253–257, 2009. View at Scopus
  48. M. I. Morsi, A. I. Youssef, M. E. Hassouna, A. S. El-Sedafi, A. A. Ghazal, and E. R. Zaher, “Telomerase activity, cytokeratin 20 and cytokeratin 19 in urine cells of bladder cancer patients,” Journal of the Egyptian National Cancer Institute, vol. 18, no. 1, pp. 82–92, 2006. View at Scopus
  49. J. Wang, L. Wu, J. Ren, and X. Qu, “Visualizing human telomerase activity with primer-modified Au nanoparticles,” Small, vol. 8, no. 2, pp. 259–264, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. I. Iwabuchi, K. Mori, H. Yamamoto et al., “Significance of A simple assay of urine telomerase activity for the detection of bladder cancer,” Acta Urologica Japonica, vol. 56, no. 10, pp. 551–557, 2010. View at Scopus
  51. S. Eissa, M. Swellam, A. Amin, M. E. Balbaa, G. A. Yacout, and T. M. El-Zayat, “The clinical relevance of urine-based markers for diagnosis of bladder cancer,” Medical Oncology, vol. 28, no. 2, pp. 513–518, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. A. S. Brems-Eskildsen, K. Zieger, H. Toldbod et al., “Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts,” BMC Cancer, vol. 10, article 646, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. L. V. Svinareva, A. I. Glukhov, O. V. Zimnik, I. I. Bykov, T. V. Khorobrykh, and V. I. Shvets, “Detection of telomerase activity in gastric cancer,” Biomeditsinskaya Khimiya, vol. 56, no. 5, pp. 602–608, 2010. View at Scopus
  54. R. Silvestrini, S. Bravaccini, V. Casadio, D. Amadori, and D. Calistri, “The current role of telomerase in the diagnosis of bladder cancer,” Indian Journal of Urology, vol. 25, no. 1, pp. 40–46, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Eissa, M. Swellam, R. Ali-Labib, A. Mansour, O. El-Malt, and F. M. Tash, “Detection of telomerase in urine by 3 methods: evaluation of diagnostic accuracy for bladder cancer,” Journal of Urology, vol. 178, no. 3, pp. 1068–1072, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Bravaccini, V. Casadio, R. Gunelli et al., “Combining cytology, TRAP assay, and FISH analysis for the detection of bladder cancer in symptomatic patients,” Annals of Oncology, vol. 22, no. 10, pp. 2294–2298, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. M. A. Sanchini, R. Gunelli, O. Nanni et al., “Relevance of urine telomerase in the diagnosis of bladder cancer,” Journal of the American Medical Association, vol. 294, no. 16, pp. 2052–2056, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Okumura, I. Mizuno, O. Nagakawa, and H. Fuse, “Telomerase activity is correlated with lower grade and lower stage bladder carcinomas,” International Journal of Urology, vol. 11, no. 12, pp. 1082–1086, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Dettlaff-Pokora, M. Matuszewski, and B. Schlichtholz, “Telomerase activity in urine sediments as a tool for noninvasive detection of bladder cancer,” Cancer Letters, vol. 222, no. 1, pp. 83–88, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Bravaccini, M. A. Sanchini, A. M. Granato et al., “Urine telomerase activity for the detection of bladder cancer in females,” Journal of Urology, vol. 178, no. 1, pp. 57–61, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. D. Calistri, A. Sanchini, D. Amadori, and R. Silvestrini, “Telomerase activity: a molecular marker for early diagnosis of bladder tumor,” Recenti Progressi in Medicina, vol. 98, no. 2, pp. 74–78, 2007. View at Scopus
  62. J. L. Campos-Fernandes, F. Descotes, J. André, P. Perrln, M. Devonec, and A. Ruffion, “Value of urinary markers in the diagnosis and follow-up of urothelial bladder tumours,” Progres en Urologie, vol. 17, no. 1, pp. 23–34, 2007. View at Scopus